Judith Klimovsky
Director/Board Member bei BIO-TECHNE CORPORATION
Vermögen: 3 Mio $ am 31.03.2024
Aktive Positionen von Judith Klimovsky
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENMAB A/S | Corporate Officer/Principal | 09.02.2017 | - |
BIO-TECHNE CORPORATION | Director/Board Member | 24.04.2024 | - |
Independent Dir/Board Member | 24.04.2024 | - |
Karriereverlauf von Judith Klimovsky
Ehemalige bekannte Positionen von Judith Klimovsky
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 20.12.2018 | 23.02.2024 |
NOVARTIS AG | Corporate Officer/Principal | 01.05.2009 | 01.02.2017 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2009 | 01.01.2017 |
Ausbildung von Judith Klimovsky
University of Buenos Aires School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Schweiz | 3 |
Dänemark | 2 |
Operativ
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BIO-TECHNE CORPORATION | Health Technology |
NOVARTIS AG | Health Technology |
GENMAB A/S | Health Technology |
Private Unternehmen | 2 |
---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Börse
- Insiders
- Judith Klimovsky
- Erfahrung